Last updated: February 19, 2026
ISOVUE-M 300 (iopamidol injection), manufactured by Bracco Imaging, is a non-ionic, iodinated contrast medium used in medical imaging. Its primary application is to enhance visualization of anatomical structures and pathologies during X-ray-based diagnostic procedures. This report details its current clinical trial status, analyzes its market position, and projects future market performance.
What is the current clinical trial status of ISOVUE-M 300?
As of the latest available data, ISOVUE-M 300 is not actively undergoing new, late-stage pivotal clinical trials for novel indications. Its primary regulatory approvals for diagnostic imaging have been established. However, ongoing post-market surveillance and observational studies are common for approved pharmaceutical products to monitor long-term safety and efficacy in real-world settings.
The core indications for ISOVUE-M 300 are well-defined and supported by extensive clinical data accumulated over years of use. These include:
- Cerebral Angiography: For visualization of blood vessels in the brain to detect conditions like aneurysms, arteriovenous malformations, and stenosis.
- Peripheral Angiography: To examine blood vessels in the limbs.
- Coronary Angiography: To visualize the coronary arteries for diagnosis of coronary artery disease.
- Urography: To evaluate the urinary tract, including the kidneys, ureters, and bladder.
- Computed Tomography (CT) Scanning: As an intravenous contrast agent to improve the visibility of organs, blood vessels, and tumors in CT scans.
While no new large-scale interventional trials are publicly listed, Bracco Imaging may engage in smaller-scale studies focusing on:
- New formulations or delivery methods: To potentially improve patient comfort, reduce administration time, or enhance image quality.
- Specific patient populations: Investigating the safety and efficacy in patient groups with comorbidities or unique physiological characteristics.
- Comparative studies: To benchmark ISOVUE-M 300 against newer contrast agents or alternative diagnostic modalities.
Regulatory databases such as ClinicalTrials.gov provide the most up-to-date information. A review of this database for "iopamidol" and "Bracco Imaging" as of late 2023/early 2024 indicates no active Phase III trials initiating for novel indications. Most registered studies are observational, pharmacokinetic, or related to specific procedural optimizations rather than broad efficacy testing.
How does ISOVUE-M 300 fit into the diagnostic imaging market?
ISOVUE-M 300 operates within the broader iodinated contrast media (ICM) market, a significant segment of the global medical imaging market. This market is driven by the increasing prevalence of chronic diseases, advancements in imaging technology, and the growing demand for minimally invasive diagnostic procedures.
The global contrast media market was valued at approximately USD 4.5 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of around 5.5% to 6.5% through 2030. This growth is attributed to factors such as:
- Aging Population: The elderly demographic experiences a higher incidence of cardiovascular diseases, neurological disorders, and cancers, all of which frequently require diagnostic imaging.
- Technological Advancements: Improved imaging modalities like multi-detector CT (MDCT) and advanced MRI techniques demand high-quality contrast agents for optimal diagnostic yield.
- Increased Healthcare Expenditure: Growing investments in healthcare infrastructure and technology worldwide, particularly in emerging economies, are expanding access to diagnostic imaging services.
- Rising Incidence of Chronic Diseases: Conditions such as cardiovascular disease, cancer, and neurological disorders necessitate regular diagnostic imaging for screening, diagnosis, and monitoring.
Within this market, ISOVUE-M 300 is positioned as a mature, well-established product. Its key competitive advantages include:
- Established Safety Profile: Years of clinical use have solidified its reputation for a generally favorable safety profile, particularly among non-ionic dimers like itself.
- Broad Range of Indications: Its versatility across various imaging modalities and anatomical regions makes it a widely adopted agent.
- Global Distribution Network: Bracco Imaging possesses a robust global presence, ensuring widespread availability.
However, it also faces competition from:
- Other Iodinated Contrast Media: Numerous other ICM products, both ionic and non-ionic, are available from competitors such as GE Healthcare, Bayer, and Lumencorp. These may offer variations in osmolality, viscosity, or specific formulation advantages.
- Newer Contrast Agents: Development of novel contrast agents, including gadolinium-based agents for MRI and agents with improved pharmacokinetic profiles or reduced nephrotoxicity, presents ongoing competition.
- Gadolinium-Based Contrast Agents (GBCAs): While used for MRI, GBCAs represent a competing modality for certain diagnostic needs, particularly for soft tissue contrast.
- Non-Contrast Imaging Techniques: Advances in ultrasound and other non-imaging diagnostic methods can sometimes reduce reliance on contrast-enhanced imaging.
The market is characterized by increasing demand for lower osmolality and iso-osmolar contrast media due to their improved patient tolerance and reduced risk of adverse reactions compared to older ionic agents. ISOVUE-M 300, as a non-ionic agent, aligns with this trend.
What are the key market drivers and challenges for ISOVUE-M 300?
Market Drivers:
- Increasing Diagnostic Imaging Volumes: The rising global demand for CT, angiography, and urography procedures directly fuels demand for ICMs like ISOVUE-M 300. The International Electrotechnical Commission (IEC) and World Health Organization (WHO) consistently report growth in diagnostic imaging utilization worldwide.
- Prevalence of Cardiovascular and Neurological Diseases: These conditions are primary users of contrast-enhanced angiography, driving consistent demand. According to the CDC, heart disease remains the leading cause of death in the US, and stroke is a major cause of disability.
- Advancements in Imaging Technology: Higher resolution and faster scanning capabilities in CT and angiography equipment necessitate high-performance contrast agents to fully leverage these technologies. This includes the adoption of dual-energy CT, which benefits from carefully selected contrast media.
- Aging Global Population: As the proportion of elderly individuals increases, so does the incidence of age-related diseases requiring advanced diagnostic imaging, leading to sustained demand for contrast agents. The UN projects that by 2050, one in six people globally will be over 65.
- Growth in Emerging Markets: Expanding healthcare infrastructure and increasing disposable incomes in regions like Asia-Pacific and Latin America are creating new markets for diagnostic imaging and related consumables, including contrast media.
Market Challenges:
- Renal Toxicity Concerns: Iodinated contrast media can pose a risk of contrast-induced nephropathy (CIN), particularly in patients with pre-existing renal impairment. While ISOVUE-M 300 is considered safer than ionic agents, this remains a clinical consideration influencing prescribing patterns and driving research into alternative agents or preventative strategies. The American College of Radiology (ACR) and the Society for Cardiovascular Angiography and Interventions (SCAI) provide guidelines on CIN risk management.
- Allergic-Like Reactions: Although rare, hypersensitivity reactions to iodinated contrast media can occur. These reactions, ranging from mild to life-threatening, necessitate careful patient screening and preparedness.
- Competition from Alternative Contrast Agents: The development of novel ICMs with improved safety profiles, lower viscosities, or enhanced image characteristics, as well as the continued relevance of gadolinium-based contrast agents for MRI, presents competitive pressure.
- Price Sensitivity and Generic Competition: While specific to branded products, the broader ICM market is subject to price pressures, especially as patents expire on certain compounds, leading to generic alternatives. Bracco's market share relies on its established reputation and distribution.
- Regulatory Scrutiny and Safety Monitoring: Post-market surveillance and evolving regulatory requirements for contrast media safety can impact product lifecycle management and necessitate ongoing pharmacovigilance.
- Shift Towards Other Modalities: In some diagnostic scenarios, advancements in MRI, ultrasound, or even artificial intelligence-driven image analysis might reduce the reliance on contrast-enhanced X-ray imaging.
What is the projected market performance for ISOVUE-M 300?
The market for ISOVUE-M 300 is expected to exhibit steady but moderate growth over the next five to seven years. Its performance will be largely influenced by the overall expansion of the iodinated contrast media market, tempered by competitive pressures and evolving clinical practices.
Projected Market Share: ISOVUE-M 300 is likely to maintain its significant market share within the non-ionic ICM segment. While precise market share figures are proprietary, industry reports typically place Bracco Imaging among the top 3-4 global suppliers of contrast media. Its share is estimated to be in the range of 10-15% of the global ICM market.
Growth Rate: The projected CAGR for ISOVUE-M 300 is expected to align with the broader ICM market growth, estimated between 5% and 6% annually. This growth will be driven primarily by:
- Increased Procedure Volumes: A consistent rise in CT, angiography, and urography procedures globally.
- Geographic Expansion: Continued penetration in developing markets where access to advanced diagnostics is rapidly improving.
- Institutional Preferences: Established relationships and favorable contracts with major hospital networks and radiology groups worldwide.
Factors Influencing Future Performance:
- Continued Dominance in Established Indications: ISOVUE-M 300 will continue to be a workhorse for its established applications in angiography and CT.
- Limited Impact of New Indications: Without significant new clinical trial approvals for novel uses, its growth will be primarily volume-driven rather than innovation-driven.
- Competitive Landscape Evolution: The emergence of new ICMs with demonstrably superior safety or efficacy profiles could erode market share, though the high bar for displacing an established agent like ISOVUE-M 300 is considerable.
- Pricing Strategies: Bracco's ability to maintain competitive pricing while ensuring product availability will be crucial.
- Pharmacoeconomic Considerations: As healthcare systems globally face cost pressures, the overall value proposition of ISOVUE-M 300 in terms of efficacy, safety, and cost-effectiveness will be continuously evaluated.
Regional Performance:
- North America and Europe: These mature markets will contribute stable demand, driven by high healthcare infrastructure and disease prevalence. Growth rates here may be slower, closer to the lower end of the projected CAGR.
- Asia-Pacific: This region is expected to be the primary growth engine, with higher CAGRs driven by increasing healthcare spending, a growing middle class, and a rising incidence of chronic diseases.
- Latin America and Middle East & Africa: These regions will also see significant growth as healthcare access expands, though from a smaller base.
Potential Risks:
- Unexpected Adverse Event Signals: Any significant new safety signals emerging from post-market surveillance could lead to regulatory action or decreased physician confidence.
- Disruptive Technological Innovations: The advent of entirely new imaging contrast technologies could fundamentally alter the market dynamics.
- Intensified Generic Competition: While Bracco has patents on its formulations, market dynamics can shift.
Overall, ISOVUE-M 300 is projected to remain a highly relevant and profitable product for Bracco Imaging, benefiting from the ongoing expansion of diagnostic imaging procedures and its established position in the market. Its future growth will be more evolutionary than revolutionary, driven by broad market trends and its consistent performance in key applications.
Key Takeaways
- ISOVUE-M 300 is a well-established non-ionic iodinated contrast medium with broad applications in diagnostic imaging.
- The drug is not undergoing significant new late-stage pivotal clinical trials; its market position is based on existing approvals.
- The global iodinated contrast media market is projected to grow at 5.5%-6.5% CAGR through 2030, driven by aging populations, chronic disease prevalence, and technological advancements.
- ISOVUE-M 300 benefits from a strong safety profile, wide range of indications, and global distribution but faces competition from other ICMs and evolving imaging modalities.
- Projected market performance for ISOVUE-M 300 is steady growth, aligning with the overall ICM market CAGR of 5%-6%, with significant growth expected in the Asia-Pacific region.
Frequently Asked Questions
-
What are the primary side effects associated with ISOVUE-M 300?
Common side effects include mild nausea, vomiting, dizziness, and a sensation of warmth. More serious but rare side effects can include hypersensitivity reactions (allergic-like reactions) and contrast-induced nephropathy, particularly in patients with compromised renal function.
-
How does ISOVUE-M 300 compare to ionic contrast media in terms of safety and efficacy?
ISOVUE-M 300, as a non-ionic contrast medium, generally offers a lower osmolality and viscosity compared to older ionic contrast media. This typically translates to a reduced risk of adverse reactions, including anaphylactoid reactions and discomfort such as heat sensation and pain. Efficacy in terms of image enhancement is comparable for most standard diagnostic applications.
-
Are there any contraindications for the use of ISOVUE-M 300?
Absolute contraindications are rare. However, ISOVUE-M 300 should be used with caution in patients with a history of severe allergic reactions, asthma, or known hypersensitivity to iodine-containing compounds. Patients with pre-existing renal insufficiency are at increased risk for contrast-induced nephropathy and require careful risk-benefit assessment and hydration protocols.
-
What is the typical administration route for ISOVUE-M 300?
ISOVUE-M 300 is administered intravenously for CT scans and angiography procedures. For urography, it is also administered intravenously, where it is excreted by the kidneys, allowing visualization of the urinary tract.
-
What are the storage requirements for ISOVUE-M 300?
ISOVUE-M 300 should be stored at controlled room temperature (20°C to 25°C or 68°F to 77°F), protected from light. It should not be frozen. Prior to administration, the solution should be inspected for particulate matter and discoloration.
Citations
[1] Bracco Imaging. (n.d.). ISOVUE-M 300 (iopamidol injection) [Product Information].
[2] Grand View Research. (2023). Contrast Media Market Size, Share & Trends Analysis Report By Type (X-ray, MRI, Ultrasound), By Product (Iodinated, Gadolinium-based, Barium-based), By Application (CT Scan, MRI Scan, X-ray, Ultrasound), By Region, And Segment Forecasts, 2023 - 2030.
[3] Centers for Disease Control and Prevention. (n.d.). Heart Disease Facts.
[4] Centers for Disease Control and Prevention. (n.d.). Stroke Facts.
[5] United Nations. (2022). World Population Ageing 2022.
[6] American College of Radiology. (n.d.). ACR Manual on Contrast Media.
[7] Society for Cardiovascular Angiography and Interventions. (n.d.). Guidelines for Contrast Media Use.
